Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib Dose Optimization in First-Line HER2+ Advanced Breast Cancer
NCT06770296Phase 1Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pyrotinib in HER2-positive breast cancer (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective Response Rate up to 100 months. Started Nov 2024; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06770296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06770296.